Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Treating the locoregional lymph nodes with radiation and/or surgery significantly improves outcome in dogs with high-grade mast cell tumours.

Tytuł:
Treating the locoregional lymph nodes with radiation and/or surgery significantly improves outcome in dogs with high-grade mast cell tumours.
Autorzy:
Mendez SE; University of Pennsylvania, Department of Clinical Sciences & Advanced Medicine, Philadelphia, PA.
Drobatz KJ; University of Pennsylvania, Department of Clinical Sciences & Advanced Medicine, Philadelphia, PA.
Duda LE; University of Pennsylvania, Department of Clinical Sciences & Advanced Medicine, Philadelphia, PA.; University of Pennsylvania, Penn Vet Cancer Center, Philadelphia, Pennsylvania.
White P; The Oncology Service, Leesburg, Virginia.
Kubicek L; Angell Animal Medical Center, Boston, Massachusetts.
Sorenmo KU; University of Pennsylvania, Penn Vet Cancer Center, Philadelphia, Pennsylvania.; University of Pennsylvania, Department of Biomedical Sciences, Philadelphia, Pennsylvania.
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2020 Jun; Vol. 18 (2), pp. 239-246. Date of Electronic Publication: 2019 Oct 29.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Oxford, UK : Blackwell, [2003]-
MeSH Terms:
Dog Diseases/*radiotherapy
Lymph Nodes/*pathology
Lymph Nodes/*surgery
Mast-Cell Sarcoma/*veterinary
Neoplasm Recurrence, Local/*veterinary
Animals ; Antineoplastic Agents/therapeutic use ; Dog Diseases/pathology ; Dog Diseases/prevention & control ; Dogs ; Female ; Lymph Nodes/radiation effects ; Lymphatic Metastasis/prevention & control ; Male ; Mast-Cell Sarcoma/pathology ; Mast-Cell Sarcoma/radiotherapy ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Recurrence, Local/radiotherapy ; Retrospective Studies
References:
London CA, Thamm DH. Mast cell tumors. In: Withrow SJ, Vail DM, Page RL, eds. Withrow & MacEwen's small animal oncology. 5th ed. Philadelphia: Saunders; 2013:335-355.
Murphy S, Sparkes AH, Smith KC, Blunden AS, Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec. 2004;154(24):743-746.
Schultheiss PC, Gardiner DW, Rao S, Olea-Popelka F, Tuohy JL. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2011;238(11):1464-1469.
Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. 2013;196(3):492-498.
Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984;21(5):469-474.
Sabattini S, Scarpa F, Berlato D, Bettini G. Histologic grading of canine mast cell tumor: is 2 better than 3? Vet Pathol. 2015;52(1):70-73.
Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract. 1973;14(1):27-41.
Hottendorf GH, Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A. 1967;14(3):272-281.
Hume CT, Kiupel M, Rigatti L, Shofer FS, Skorupski KA, Sorenmo KU. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc. 2011;47(1):37-44.
Donnelly L, Mullin C, Balko J, et al. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Vet Comp Oncol. 2015;13(1):70-76.
Bostock DE, Crocker J, Harris K, Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer. 1989;59(6):915-918.
Hahn KA, King GK, Carreras JK. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). J Am Vet Med Assoc. 2004;224(1):79-82.
Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006;68(6):581-587.
Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol. 2009;7(2):130-138.
Pokorny E, Hecht S, Sura PA, et al. Magnetic resonance imaging of canine mast cell tumors. Vet Radiol Ultrasound. 2012;53(2):167-173.
Worley DR. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Vet Comp Oncol. 2014;12(3):215-226.
LaDue T, Price GS, Dodge R, Page RL, Thrall DE. Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound. 1998;39(1):57-62.
Contributed Indexing:
Keywords: dogs; lymph nodes; lymphatic metastasis; mast cells; skin neoplasms
Substance Nomenclature:
0 (Antineoplastic Agents)
Entry Date(s):
Date Created: 20190912 Date Completed: 20210210 Latest Revision: 20210210
Update Code:
20240105
DOI:
10.1111/vco.12541
PMID:
31509648
Czasopismo naukowe
High-grade canine mast cell tumours (HG-MCT) have a high rate of locoregional relapse. In this study, dogs with HG-MCT treated with radiation therapy (RT) were retrospectively evaluated to determine the benefit associated with treating the locoregional lymph nodes (LNs). Forty-two dogs were included. Variables assessed for association with overall survival (OS) and progression-free survival (PFS) included WHO stage, tumour location and size, LN irradiation (prophylactic, therapeutic or none), LN treatment (yes or no), LN status at RT (metastatic or nonmetastatic) and RT intent (definitive vs palliative). Lower-stage disease at irradiation was significantly associated with prolonged median PFS (425 vs 125 days for stage 0 vs 1-4), and OS (615 vs 314 days for stage 0 vs 1-4). Having any LN treatment and definitive RT were both significantly associated with prolonged OS. In order to evaluate the role of LN irradiation, dogs were divided into subgroups: (a) stage 0 at irradiation with no LN treatment (n = 14), (b) stage 0 at irradiation with prophylactic LN irradiation (n = 6), (c) stage 0 at irradiation but previously stage 2 (n = 5) and (d) stage >0 at irradiation (n = 17). Prophylactic LN irradiation significantly prolonged PFS (>2381 vs 197 days; group B vs A). Interestingly, dogs that were stage 2 and had LN treatment (C) had prolonged OS vs dogs with negative LNs and no LN treatment (A) (1908 vs 284 days; P = .012). This study confirms that prophylactic and therapeutic LN irradiation in dogs with HG-MCT is beneficial and improves outcome.
(© 2019 John Wiley & Sons Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies